Friday, April 29, 2011
Thursday, April 28, 2011
Dear bioOrlando Members:
The Senate and House started the budget conference process this morning. Late Tuesday night, the Senate and House appointed their budget negotiators ("conferees"). Budget conferees will meet over the next 5 days to work out the differences between the two budgets.
NEED YOUR HELP! Biomedical research funding is in danger of being eliminated this year, as legislators attempt to balance the state budget amid an almost $4 billion budget deficit. Click here.
Currently, the House funds the James and Esther King Biomedical Research Program (King) at $1.2 million and eliminates funding for the Bill Bankhead and David Coley Biomedical Research Program (Bankhead-Coley). The Senate funds King at $12.2 million and Bankhead-Coley at $10 million. The Senate also allocates $10 million each to the H. Lee Moffitt Cancer Center and Research Institute, the Shands Cancer Hospital and the Sylvester Cancer Center at the University of Miami.
Florida's Biomedical Research Programs:
- Increase Florida's biomedical and cancer researchers' national funding competitiveness;
- Facilitate collaborations between talented scientists within Florida, nationally and internationally;
- Expand research capacity through the training of new scientists and provision of research instruments; and
- Bolster the Florida's investment to grow its technology-based economy in the biosciences.
Please email the Senate and House Health Care Conferees
Senate Health Care Budget Conferees
Sen. Joe Negron - firstname.lastname@example.org
Sen. Anitere Flores - email@example.com
Sen. Rene Garcia - firstname.lastname@example.org
Sen. Jim Norman - email@example.com
Sen. Garrett Richter - firstname.lastname@example.org
Sen. Eleanor Sobel - email@example.com
House Health Care Budget Conferees
Rep. Matt Hudson - firstname.lastname@example.org
Rep. Charles "Chuck" Chestnut - email@example.com
Rep. Richard Corcoran - firstname.lastname@example.org
Rep. Daniel Davis - email@example.com
Rep. Jose Diaz - firstname.lastname@example.org
Rep. Jim Frishe - email@example.com
Rep. Gayle Harrell - firstname.lastname@example.org
Rep. Mia Jones - email@example.com
Rep. Mark Pafford - firstname.lastname@example.org
Rep. Ken Roberson - email@example.com
Rep. Greg Steube - firstname.lastname@example.org
Rep. John Wood - email@example.com
Rep. Dana Young - firstname.lastname@example.org
Thank you for helping bioOrlando support Florida's Biomedical Research Programs!
Wednesday, April 27, 2011
4.28.11 / MAP 318 / 3-4pm / Seminar: “Simulating Photonic Interactions with Graphical Methods: Numerical Modeling without Writing Software” – Mary Pot
MAP 318 – Department of Mathematics
Thursday, April 28, 2011 / 3:00pm-4:30pm
Dr. Mary Potasek
Formulating a numerical model for photo-physical interactions is complex, often requiring additional effort when the actual optical experiments involve materials of different types of nonlinearities, multi-photon absorptions/relaxations, photo-induced energy transfer, up-conversion, stimulated emission, Auger process, in organics/inorganics and quantum dots with different types of electronic level transitions. We illustrate a method based on computational transition modules (photonic building blocks), which allows simulating a wide range of photonic interactions without reformulating the propagation-material equations and rewriting or editing the simulation code.
For More Information:
Dr. Demetrios Christodoulides
ORLANDO, FL (April 18, 2011) – If your company falls into one of the sectors listed below, it’s eligible to compete for a Governor’s Business Diversification Award. It recognizes businesses for making noteworthy contributions toward Florida’s economic development efforts.
· Corporate Headquarters
· Emerging Industries
· Financial/Professional Services
· Homeland Security/Defense
· Information Technology
· Life Sciences
· Trade/Export Services
The entry deadline is June 24 at 5 p.m. ET., and the application will be available online via Enterprise Florida’s Web site, www.eflorida.com/govawards, starting April 18.
The nomination of a business can be made by a local or regional economic development organization, or a professional or industry association. Self-nominations are acceptable, also. Three awards will be given in each of these categories:
· Governor’s Business Expansion Award: For Florida companies that expanded their operations in 2010, investing capital and creating jobs for Floridians.
· Governor’s Newcomer Award: For new-to-Florida companies that began business operations in 2010.
· Governor’s Export Excellence Award: For Florida companies with new or significant increases in documented export sales in 2010.
· Governor’s Entrepreneurship Award: For Florida start-up companies (less than 5 years old) that have set a standard for entrepreneurship and creativity.
· Governor’s Innovation Award: For Florida companies, organizations or institutions that through product or process best exemplified innovative leadership in 2010.
· Governor’s Green-to-Gold Award: For Florida companies that through product or process best exemplified "green" leadership as it pertains to the state's goal to become a leader in this emerging field.
-- more --
The winners will be announced in September during Industry Appreciation Week, the third week of the month. The awards will be presented at that time during a special event.
Corporate sponsors for this program this year are Bank of America and Florida Trend.
For more information about the Governors Business Diversification Awards and entry requirements, businesses and economic development organizations can contact:
External Affairs Program Manager
(850) 298-6638 or email@example.com
* * *
Enterprise Florida, Inc. is a partnership between Florida's business and government leaders and is the principal economic development organization for the state of Florida. Headquartered in Orlando, Enterprise Florida’s mission is to diversify Florida’s economy and create better-paying jobs for its citizens by supporting, attracting and helping to create businesses in innovative, high-growth industries. In pursuit of its mission, Enterprise Florida works closely with a statewide network of economic development partners and is funded both by the State of Florida and by private-sector businesses.
Tuesday, April 26, 2011
LPTH Press Release - Lightpath Technologies Introduces New IR Lenses at the SPIE Defense, Security And Sensing Conference
LIGHTPATH TECHNOLOGIES INTRODUCES TWO NEW NEW INFRARED OPTICS
LIGHTPATH TECHNOLOGIES ADDS NEW LENSES TO ITS LONG WAVE INFRARED (LWIR) CATALOG
--Targets Large Addressable Markets including Homeland Security--
Orlando, FL - (April 26, 2011) - LightPath Technologies, Inc. (Nasdaq: LPTH), a global manufacturer, distributor and integrator of patented optical components and assemblies, announced today it has added new molded infrared aspheres to its catalog of Long Wave Infrared (LWIR) lenses. These lenses are designed as the primary optics for thermal imagers used in a wide variety of applications including homeland security, firefighting, predictive maintenance and driver’s vision enhancement systems in automobiles. These infrared markets have a combined current estimated value of over $2.5 billion.
This new lens is a low cost thermal imaging lens designed specifically for the high volume thermal imaging security camera market. Its f/1.3 and 7.7mm focal length design is optimized for use with the latest generation of 640x512, 17 micron pixel infrared detectors from all of the major thermal imaging camera core suppliers. These new lenses are manufactured from LightPath’s Black Diamond ™ chalcogenide glass and are a less expensive substitute for high-volume, diamond-turned Germanium and Zinc Selenide optics.
“LightPath Technologies is continuing to expand its product offering for Infrared Optics with the introduction of these lenses. These new products will address the rapidly expanding thermal imaging and night vision enhancement markets that required high volumes of infrared optics at prices that are lower than currently available,” said Jim Gaynor, CEO and President of LightPath.
LIGHTPATH TECHNOLOGIES ADDS NEW MID-WAVE INFRARED COLLIMATOR TO ITS CATALOG
--Targets Growing Markets including IRCM & Gas Sensing--
Orlando, FL - (April 26, 2011) - LightPath Technologies, Inc. (Nasdaq: LPTH), a global manufacturer, distributor and integrator of patented optical components and assemblies, announced today it has added a new Mid-Wave Infrared (MWIR) fiber collimator using LightPath’s molded infrared aspheres. This collimator is designed as a beam expanding optic for MWIR fibers or as a collimating lens for Quantum Cascade Lasers (QCL) used in a wide variety of applications including infrared countermeasures (IRCM), and gas analytical instrumentation for environmental sensing. These infrared markets are growing rapidly as the cost of MWIR laser sources continues to decline.
This new collimator is based on LightPath’s existing MWIR collimating lenses and extends our existing product line of collimators into the infrared. These new lenses are manufactured from LightPath’s Black Diamond ™ chalcogenide glass and are a less expensive substitute for high-volume, diamond-turned Germanium and Zinc Selenide optics.
“LightPath Technologies is continuing to expand its product line for Infrared Optics with the introduction of these collimators. These new products are an expansion of our business in high performance molded aspheres for laser collimation. The combination of LightPath’s experience in laser collimation and our new Black Diamond infrared optics is proving to be an excellent market for our unique capabilities,” said Jim Gaynor, CEO and President of LightPath.
About LightPath Technologies
LightPath manufactures optical products including precision molded aspheric optics, GRADIUM® glass products, proprietary collimator assemblies, laser components utilizing proprietary automation technology, higher-level assemblies and packing solutions. LightPath has a strong patent portfolio that has been granted or licensed to us in these fields. LightPath common stock trades on the Nasdaq Capital Market under the stock symbol LPTH. For more information visit www.lightpath.com
Contact: Ray Pini, Director of Marketing
LightPath Technologies, Inc.
Phone: +1-407-382-4003 x336
This news release includes statements that constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This information may involve risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, factors detailed by LightPath Technologies, Inc. in its public filings with the Securities and Exchange Commission. Except as required under the federal securities laws and the rules and regulations of the Securities and Exchange Commission, we do not have any intention or obligation to update publicly any forward-looking statements whether as a result of new information, future events or otherwise.
GRADIUM® is a registered trademark of LightPath Technologies
Monday, April 25, 2011
Saturday, April 23, 2011
Thursday, April 21, 2011
5.12.11 / CREOL 102 / 11-12pm / Seminar: “Novel Therapeutic and Diagnostic Applications of Lasers in Medicine”, Nathaniel Fried, University of North C
Seminar: “Novel Therapeutic and Diagnostic Applications of Lasers in Medicine”, Nathaniel Fried, University of North Carolina
Thursday, May 12, 2011 / 11:00am-12:00pm
Nathaniel Fried, Ph.D.
Department of Physics and Optical Science
University of North Carolina at Charlotte
The Biomedical Optics Laboratory at UNC-Charlotte is devoted to development of novel therapeutic and diagnostic laser applications in medicine. The lab performs applied, clinically-driven research and provides a bridge between physicists/engineers and doctors. This presentation provides an overview of promising laser technologies for potential treatment or diagnosis of “Quality-of-Life” problems in urology:
(1) Thulium fiber laser vaporization of kidney stones:
The solid-state Holmium:YAG laser (=2120 nm) currently used for lithotripsy is limited by its poor spatial beam profile – the large fibers used may break, damaging endoscopes, and prevent sufficient saline irrigation, compromising visibility and safety. Fiber lasers provide high power coupling into smaller, more flexible fibers for use in latest flexible endoscopes, with improved bending and higher irrigation rates. The thulium fiber laser (=1908 nm) matches a major water absorption peak in tissue, thus providing lower ablation thresholds and more efficient stone ablation than the Holmium laser.
(2) Erbium:YAG laser incision of urethral strictures using mid-infrared optical fibers:
Endoscopic applications of mid-IR lasers have been limited due to the lack of a suitable fiber delivery system. A hybrid germanium oxide/sapphire fiber is a biocompatible, flexible, robust, high-power fiber for endoscopic delivery of Erbium:YAG laser radiation (=2940 nm). The Erbium laser may provide precise, cellular level vaporization of scar tissue in the urinary tract for treatment of incontinence.
(3) Noninvasive laser vasectomy using a Ytterbium fiber laser:
Vasectomy is the most effective, safest, and least expensive method of sterilization. However, due to male fears of incision, bleeding, infection, and pain associated with surgical vasectomy, female sterilization (tubal ligation) remains more popular. Deeply penetrating near-infrared Ytterbium fiber laser radiation (=1075 nm) in conjunction with cryogen spray cooling, can be used to perform noninvasive male sterilization which may increase the popularity of vasectomy.
(4) Optical coherence tomography (OCT) of the prostate nerves:
The cavernous nerves course along the prostate surface and are responsible for sexual function. Surgeons have difficulty identifying and sparing these nerves during prostate cancer surgery. OCT is an ideal technology for high-resolution imaging of these nerves and can easily be integrated into standard laparoscopic and robotic instruments for intra-operative diagnosis.
(5) Infrared laser stimulation of the cavernous nerves:
Optical nerve stimulation (ONS) using pulsed infrared light has recently been developed as an alternative to conventional electrical nerve stimulation. ONS provides several advantages, including non-contact stimulation, increased spatial selectivity, and elimination of stimulation artifacts. Our laboratory is investigating ONS as an intra-operative fiber optic method that complements OCT for identification of the cavernous nerves.
Nathaniel Fried is currently an Associate Professor in the Department of Physics and Optical Science and Director of the Biomedical Optics Laboratory at the University of North Carolina at Charlotte, and an Adjunct Assistant Professor in the Department of Urology at Johns Hopkins Medical School, in Baltimore, MD. Dr. Fried received his Ph.D. in Biomedical Engineering from Northwestern University in 1998 while working in the area of laser tissue welding. As a joint postdoctoral fellow at the Johns Hopkins Applied Physics Laboratory and the Department of Biomedical Engineering at Johns Hopkins Medical School, he worked on designing novel laser balloon catheters for use in treating cardiac arrhythmias. From 2000-2006, he was a faculty member in the Department of Urology at Johns Hopkins Medical School and the Director of the Biomedical Optics Laboratory at Johns Hopkins Bayview Medical Center. Dr. Fried has over 15 years of experience working in the field of laser-tissue interactions and laser medicine. He has been a member of both the American Society for Laser Medicine and Surgery (ASLMS) and the Society of Photo-Instrumentation Engineers (SPIE) since 1998, and he currently serves as an editorial board member for the journals, Lasers in Surgery and Medicine and Lasers in Medical Science. Dr. Fried has published over 100 manuscripts, conference proceedings, and book chapters in laser medicine and currently holds several patents in the field. He is the past recipient of three Young Investigator Awards for his research in laser medicine, and he has received extramural research funding from a number of federal agencies (NIH, DOD, DOE, USAID), private foundations (Whitaker, NKF), and industry. In addition to actively performing research in the field of laser medicine, Dr. Fried also currently teaches an undergraduate introductory course in Medical Physics and a graduate course in Biomedical Optics at UNC-Charlotte.
For More Information:
Dr. Eric W. Van Stryland